Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Carbon footprint impact of the choice of inhalers for asthma and COPD
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Lung- allergy- and sleep research.ORCID iD: 0000-0001-5093-6980
GlaxoSmithKline, Environm Hlth Safety & Sustainabil, London, England.
GlaxoSmithKline, Worldwide Med Affairs Europe Mid Size & Cluster R, Stockholm, Sweden.
Polyfuture Inst SWC AB, Nacka, Sweden.
Show others and affiliations
2020 (English)In: Thorax, ISSN 0040-6376, E-ISSN 1468-3296, Vol. 75, no 1, p. 82-84Article in journal (Refereed) Published
Abstract [en]

In the 1990s, metered dose inhalers (MDIs) containing chlorofluorocarbons were replaced with dry-powder inhalers (DPIs) and MDIs containing hydrofluorocarbons (HFCs). While HFCs are not ozone depleting, they are potent greenhouse gases. Annual carbon footprint (CO(2)e), per patient were 17 kg for Relvar-Ellipta/Ventolin-Accuhaler; and 439 kg for Seretide-Evohaler/Ventolin-Evohaler. In 2017, 70% of all inhalers sold in England were MDI, versus 13% in Sweden. Applying the Swedish DPI and MDI distribution to England would result in an annual reduction of 550 kt CO(2)e. The lower carbon footprint of DPIs should be considered alongside other factors when choosing inhalation devices.

Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2020. Vol. 75, no 1, p. 82-84
Keywords [en]
asthma pharmacology, COPD pharmacology, inhaler devices
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:uu:diva-402378DOI: 10.1136/thoraxjnl-2019-213744ISI: 000503800300013PubMedID: 31699805OAI: oai:DiVA.org:uu-402378DiVA, id: diva2:1389293
Funder
GlaxoSmithKline (GSK)Available from: 2020-01-29 Created: 2020-01-29 Last updated: 2020-01-29Bibliographically approved

Open Access in DiVA

fulltext(324 kB)15 downloads
File information
File name FULLTEXT01.pdfFile size 324 kBChecksum SHA-512
0a04d63b440a6780ef95f94862e9cf39d43e87724982932b3e0eeeb03513cbd48c9c60ac9a0580eb3feef124a5c0ad673e89218c5c1c80b16b7e5df0fda41848
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jansson, Christer
By organisation
Lung- allergy- and sleep research
In the same journal
Thorax
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar
Total: 15 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 50 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf